p21WAF1 and tumourigenesis: 20 years after
NA Warfel, WS El-Deiry - Current opinion in oncology, 2013 - journals.lww.com
Current opinion in oncology, 2013•journals.lww.com
Since its discovery, it has become increasingly clear that p21 can function as both a
classical tumour suppressor and an oncogene. In order to effectively utilize p21 as a
therapeutic target, it will be necessary to design therapeutic strategies that preferentially
block the ability of p21 to promote senescence, stem cell renewal and cyclin/CDK activation,
while leaving its tumour suppressive functions intact.
classical tumour suppressor and an oncogene. In order to effectively utilize p21 as a
therapeutic target, it will be necessary to design therapeutic strategies that preferentially
block the ability of p21 to promote senescence, stem cell renewal and cyclin/CDK activation,
while leaving its tumour suppressive functions intact.
Summary
Since its discovery, it has become increasingly clear that p21 can function as both a classical tumour suppressor and an oncogene. In order to effectively utilize p21 as a therapeutic target, it will be necessary to design therapeutic strategies that preferentially block the ability of p21 to promote senescence, stem cell renewal and cyclin/CDK activation, while leaving its tumour suppressive functions intact.
Lippincott Williams & Wilkins